Vachlas Konstantinos, Zisis Charalambos, Rontogianni Dimitra, Tavernarakis Antonios, Psevdi Argini, Bellenis Ion
Department of Thoracic and Vascular Surgery, Evangelismos Hospital, Athens, Greece.
Asian Cardiovasc Thorac Ann. 2012 Feb;20(1):48-52. doi: 10.1177/0218492311433189.
Myasthenia gravis is present in a significant proportion of patients with thymoma. We investigated particular features of the clinical behavior of thymoma and its relationship to myasthenia in a retrospective study of 79 patients who underwent thymectomy for thymoma during the last 20 years. The presence of myasthenia gravis, Masaoka stage, World Health Organization histotype, myasthenia response, and survival were analyzed. The mean age of the patients was 56.1 ± 12.4 years, and 39 had myasthenia gravis. A significantly higher proportion of patients with myasthenia was found in B2 and B3 histotypes compared to A, AB, and B1. Among myasthenic patients, 33.3% had no response, 50% had a partial response, and 16.7% achieved complete remission. During the follow-up period, 16 (21.1%) patients died. Mean survival was 4.8 ± 1.4 years for patients with no myasthenia response, whereas those with a partial or complete myasthenia response had significantly better survival.
重症肌无力在相当一部分胸腺瘤患者中存在。在一项对过去20年间因胸腺瘤接受胸腺切除术的79例患者的回顾性研究中,我们调查了胸腺瘤临床行为的特殊特征及其与重症肌无力的关系。分析了重症肌无力的存在情况、马萨oka分期、世界卫生组织组织学类型、重症肌无力反应及生存率。患者的平均年龄为56.1±12.4岁,其中39例患有重症肌无力。与A、AB和B1组织学类型相比,B2和B3组织学类型中重症肌无力患者的比例显著更高。在重症肌无力患者中,33.3%无反应,50%有部分反应,16.7%实现完全缓解。在随访期间,16例(21.1%)患者死亡。无重症肌无力反应的患者平均生存期为4.8±1.4年,而有部分或完全重症肌无力反应的患者生存期明显更好。